Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised

Edwards Lifesciences Corp

2025-FY EPS reported $1.83 revenue$6,067,600,000

Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).
TAVR sales $1.16B (+12.0%); TMTT sales $156M (+40%). Full-year sales growth 11.5%.
FY2026 outlook: constant-currency sales growth 8–10%, adjusted EPS $2.90–$3.05.
FDA approved SAPIEN M3, first transcatheter mitral replacement; CMS opened TAVR NCD reconsideration.
Q1 2026 guidance: sales $1.55–$1.63B, adjusted EPS $0.70–$0.76.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.